XML 32 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Event
 6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Event Subsequent EventIn July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (“Ixo-vec”), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. The Company expects these restructuring measures will be sufficient to fully support its Ixo-vec development plan and extend its expected cash runway into 2025. The Company expects the restructuring to be completed in the fourth quarter of 2022.Under the restructuring plan, the Company reduced its workforce by 78 employees (approximately 38%) and will incur aggregate restructuring charges of approximately $4.2 million, of which it expects approximately $4.1 million will be cash expenditures. The restructuring costs will be recorded primarily in the third quarter of 2022.